Key Takeaways
- Sequential recovery, YoY mint drag: Revenue, gross profit and EBITDA all improved sequentially on better volumes and mix, but the quarter stayed well below last year's strong Q4 because U.S. tariff uncertainty crushed mint export volumes.
- Dahej is live but phenol is on hold: The entire Dahej facility went live in April 2026 and cooling-agent production has begun, yet the phenol-derivative plant sits production-ready and idle because geopolitical disruption made the key raw material too expensive and volatile to run a continuous process.
- Gross margin jumped to ~30%: Material cost fell to ~69% of revenue in Q4, lifting gross margin sharply, though the precise driver was not clearly explained on the call.
- FY27 guidance is explicitly deferred: Management declined to give revenue or margin guidance for FY27, citing the war-like geopolitical situation, and said it will be better placed to guide in one or two quarters.
- What to watch next quarter: Whether phenol prices find an equilibrium that lets the derivative plant start, the pace of Dahej utilization ramp as customer audits progress, and any concrete FY27 guidance once geopolitical fog clears.
The Mint Shock: What Broke and What Is Coming Back
- Tariff whiplash hit volumes hard: Multiple U.S. tariff announcements at different times meant clarity arrived only toward end of February, so the usual January–March order execution window for U.S. exports never materialized; the dip is primarily volume-driven, with some realization pressure.
- Utilization collapsed with mint: GEM-level capacity utilization fell from ~80%+ in Q4 FY25 to 60–65% in Q4 FY26, overwhelmingly because of the mint segment.
- Momentum is returning now: Orders are coming back and business momentum is picking up as tariff clarity has finally settled; the GST-related headwind that compounded earlier pain is also fully resolved and the business is back to its pre-GST normal.
- Mint-plus-clove ambition intact: Management expects the combined mint and clove business to exceed FY25's standalone revenue of ₹500 cr, signaling confidence that the diversification strategy absorbs the mint shock over time.
Vora: "These are uncertain times. I think we would like to wait for another, few months till this war-like situation settles down and we get adequate clarity."
Dahej: Live, Audited, and Waiting on One Big Piece
- Full facility went live in April 2026: Commercial production of Gemcool 5 and Safranal began on February 26, and the entire Dahej complex was operational by April.
- Cooling agents are the early bright spot: The company has installed India's largest cooling-agent capacity, representing almost 10% of global volume; the product is tariff-exempt from India to the U.S. while Chinese competitors face tariffs, creating a structural advantage management is "extremely bullish" about.
- Customer audits are the gating item: The factory is undergoing audits by various certifying agencies, with a host of customers at different stages of evaluation; a significant portion of qualification activity should conclude in the next two quarters, unlocking CMO and CDMO services.
- Phenol-derivative plant is ready but idle: The plant was ready as of March with catalyst prepared, but management intentionally held off starting because the continuous process cannot be stopped once begun, and elevated, fluctuating phenol prices from geopolitical disruption made consistent supply too risky.
- Restart condition is price equilibrium: The plant will restart when phenol prices cool down or at least find an equilibrium; management sees clarity on the horizon and expects better ramp-up of phenol verticals by Q1 and Q2 of the following years.
Parekh: "Because in the continuous plants, once you start, you cannot stop the production process. And if the consistency of the supply in terms of pricing is not available, it becomes a very risky proposition for us to continue."
Margin Trajectory
- Gross margin shot up to ~30% in Q4: Material cost fell to ~69% of revenue, a sharp improvement, though the call did not clearly explain the driver due to audio issues.
- Operating leverage is the forward thesis: Management expects operating leverage benefits to further support margin and profitability as business momentum improves and Dahej ramps up; margins are gradually moving toward normalized levels.
- Depreciation is a persistent drag: Profitability continued to be impacted by higher depreciation following the capitalization of a substantial portion of the Dahej capex.
- FY28 margin target set: Consolidated EBITDA margin range of 16%–18% on a turnover target of ₹1,100 cr, giving a multi-year anchor even as near-term guidance stays deferred.
Diversification: Non-Mint, Cooling Agents, and the CMO Bet
- Non-mint traction is real: Encouraging traction across non-mint products, particularly clove and its derivatives, in line with the long-term diversification strategy.
- Cooling agents have a tariff-arbitrage tailwind: The product is tariff-exempt from India to the U.S. while Chinese competitors face tariffs; major application is currently outside India, but management expects domestic demand and uses to expand in the near years.
- CMO/CDMO services are the next unlock: The objective is to start catering to CMO and CDMO services from Dahej once the ongoing qualification activity concludes, which management expects largely in the next two quarters.
- Anisole economics remain opaque: Management declined to guide on gross margin for Anisole, saying it is waiting for raw-material margins to stabilize and production to begin; the internal-vs-external consumption split also has no benchmark since production has not started.
Parekh: "From China you have tariffs, in India to the U.S. this is a tariff-exempt product. So these were the reasons why we decided to start and get into the entire cooling agent vertical."
What Management Will Not (Yet) Say
- No FY27 guidance: Management declined to give revenue or EBITDA guidance for FY27, saying uncertain times demand waiting a few months until the war-like situation settles; it will be better placed in one or two quarters.
- No current Dahej utilization number: Management called out peak revenue potential of ₹800 cr for Dahej but refused to give a current utilization figure, saying the denominator is too high and the number would look misleadingly low; guidance is deferred to H2.
- No product-wise contribution split: The company does not disclose product-wise contribution, so the exact mint share in Q4 FY25 versus Q4 FY26 was not provided.
- No synthetic-vs-natural menthol margin split: Management declined to break out price and gross margin differences, saying it looks at solutions across 40+ mint products rather than individual comparisons.
- U.S. export share for Q4 not disclosed on call: Management said it would get back to the analyst on the exact Q4 U.S. number; full-year U.S. export share is ~30%, but comparing that to a 45% Q4 decline is misleading because Q4 is historically the heaviest U.S. quarter.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Consolidated turnover target | ₹1,100 cr | FY28 |
| Consolidated EBITDA margin range | 16%–18% | FY28 |
| Mint-plus-clove combined revenue | Exceed FY25 standalone revenue of ₹500 cr | No date (implied FY27 or later) |
| Phenol-derivative plant ramp-up | Better ramp-up of phenol verticals | Q1 and Q2 of the following years (FY27) |
| Dahej CMO/CDMO qualification | Significant portion of qualification activity concluded | Next two quarters |
| FY27 guidance | Will be better placed to provide | One or two quarters from now |
| Phenol plant restart | When phenol prices cool down or find equilibrium | No date (condition-based) |
| Dahej utilization guidance | Closer to H2 can give a good utilization number | H2 FY27 |
| FY27 performance | More or less in line with scaling up, much better and closer to FY25 versus FY26 | FY27 |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Standalone revenue | ₹112 cr, +34% QoQ |
| Consolidated revenue | ₹110 cr, +40% QoQ |
| Standalone gross profit | ₹26 cr, +70% QoQ |
| Consolidated gross profit | ₹34 cr, +70% QoQ |
| Standalone gross margin | 23.4%, improved sequentially |
| Consolidated gross margin | 30.5%, improved sequentially |
| Standalone EBITDA | ₹15 cr, +98% QoQ |
| Consolidated EBITDA | ₹16 cr, +124% QoQ |
| Standalone EBITDA margin | 13.4%, improved sequentially |
| Consolidated EBITDA margin | 14.2%, improved sequentially |
| Standalone PAT | ₹12 cr, +182% QoQ |
| Consolidated PAT | ₹1 cr, vs loss of ₹5 cr in Q3 |
| Standalone cash PAT | ₹13 cr, +114% QoQ |
| Consolidated cash PAT | ₹10 cr, +170% QoQ |
| FY28 target consolidated revenue | ₹1,100 cr |
| FY28 target EBITDA margin | 16% to 18% |
| Dahej project capex incurred | ~₹260 cr of ~₹270 cr planned, substantially capitalized |
| Dahej peak revenue potential | ~₹800 cr, asset turn of 3–3.5x |
| GEM-level capacity utilization | 60–65%, down from ~80%+ in Q4 FY25 |
| FY26 export share | 44% export, 56% domestic |
| Promoter holding increase | 2% in March 2026 |